Teleflex Incorporated $TFX Shares Sold by Arax Advisory Partners

Arax Advisory Partners lowered its position in Teleflex Incorporated (NYSE:TFX) by 83.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,872 shares of the medical technology company’s stock after selling 98,776 shares during the period. Arax Advisory Partners’ holdings in Teleflex were worth $2,425,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in TFX. Barclays PLC lifted its holdings in shares of Teleflex by 21.3% in the 4th quarter. Barclays PLC now owns 4,028 shares of the medical technology company’s stock valued at $492,000 after buying an additional 708 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in Teleflex by 13.5% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 749,992 shares of the medical technology company’s stock valued at $91,529,000 after buying an additional 89,192 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in Teleflex during the fourth quarter worth $45,000. CANADA LIFE ASSURANCE Co boosted its position in Teleflex by 1.6% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 38,512 shares of the medical technology company’s stock worth $4,701,000 after purchasing an additional 613 shares in the last quarter. Finally, Walleye Capital LLC boosted its position in Teleflex by 270.8% during the fourth quarter. Walleye Capital LLC now owns 319,168 shares of the medical technology company’s stock worth $38,951,000 after purchasing an additional 233,102 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Stock Down 0.2%

TFX stock opened at $130.24 on Monday. Teleflex Incorporated has a one year low of $100.18 and a one year high of $139.67. The company has a 50 day moving average price of $128.67 and a two-hundred day moving average price of $118.98. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55. The stock has a market capitalization of $5.77 billion, a P/E ratio of -5.71, a PEG ratio of 0.97 and a beta of 0.82.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $1.21 by $0.18. The business had revenue of $548.30 million during the quarter, compared to the consensus estimate of $536.91 million. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The business’s revenue for the quarter was up 32.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.44 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, sell-side analysts expect that Teleflex Incorporated will post 6.7 EPS for the current year.

Teleflex Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Monday, May 25th will be given a $0.34 dividend. The ex-dividend date of this dividend is Friday, May 22nd. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. Teleflex’s dividend payout ratio (DPR) is currently -5.96%.

Analyst Upgrades and Downgrades

TFX has been the subject of a number of research analyst reports. Raymond James Financial restated an “outperform” rating and issued a $150.00 price target on shares of Teleflex in a research report on Friday, May 8th. Mizuho set a $140.00 target price on shares of Teleflex in a research report on Friday, May 8th. Needham & Company LLC upped their price target on shares of Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Wall Street Zen lowered shares of Teleflex from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Zacks Research upgraded Teleflex from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $146.00.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.